Joel S Benjamin, Abigail Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom, Zahra Bahrami Dizicheh, I-Ling Chen, Anh N Diep, Shi Shi, Nives Ivic, Caroline Bonnans, Alex Owyang, Pranidhi Sood, Germaine Fuh, Maike Schmidt, Kimberline Y Gerrick, Patrick Koenig, Mauro Poggio
{"title":"23ME-01473是一种Fc效应因子增强型抗ULBP6/2/5抗体，它能通过NKG2D和FcγRIIIa激活恢复NK细胞介导的抗肿瘤免疫。","authors":"Joel S Benjamin, Abigail Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom, Zahra Bahrami Dizicheh, I-Ling Chen, Anh N Diep, Shi Shi, Nives Ivic, Caroline Bonnans, Alex Owyang, Pranidhi Sood, Germaine Fuh, Maike Schmidt, Kimberline Y Gerrick, Patrick Koenig, Mauro Poggio","doi":"10.1158/2767-9764.CRC-24-0478","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":"5 3","pages":"476-495"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927390/pdf/","citationCount":"0","resultStr":"{\"title\":\"23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.\",\"authors\":\"Joel S Benjamin, Abigail Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom, Zahra Bahrami Dizicheh, I-Ling Chen, Anh N Diep, Shi Shi, Nives Ivic, Caroline Bonnans, Alex Owyang, Pranidhi Sood, Germaine Fuh, Maike Schmidt, Kimberline Y Gerrick, Patrick Koenig, Mauro Poggio\",\"doi\":\"10.1158/2767-9764.CRC-24-0478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Significance: </strong>This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.</p>\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\"5 3\",\"pages\":\"476-495\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927390/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.
Significance: This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
